Search Results - "Quartino, Angelica L."

Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results by Vavere, Andrea L, Sinsakul, Marvin, Ongstad, Emily L, Yang, Ye, Varma, Vijayalakshmi, Jones, Christopher, Goodman, Joanne, Dubois, Vincent F S, Quartino, Angelica L, Karathanasis, Sotirios K, Abuhatzira, Liron, Collén, Anna, Antoniades, Charalambos, Koren, Michael J, Gupta, Ruchi, George, Richard T

“…Background Blockade of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a potentially attractive mechanism for lowering inflammatory and…”
Get full text

Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel by Krishnan, Sreenath M., Laarif, Sofiene S., Bender, Brendan C., Quartino, Angelica L., Friberg, Lena E.

“…Information on individual lesion dynamics and organ location are often ignored in pharmacometric modeling analyses of tumor response. Typically, the sum of…”
Get full text

Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling by Quartino, Angelica L., Karlsson, Mats O., Lindman, Henrik, Friberg, Lena E.

“…Purpose Neutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC) are mainly regulated by granulocyte colony stimulating factor (G-CSF)…”
Get full text

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide by Clewe, Oskar, Rekić, Dinko, Quartino, Angelica L., Carlsson, Björn, Higashimori, Mitsuo, Wernevik, Linda, Hofherr, Alexis, Rydén‐Bergsten, Tina, Nilsson, Catarina, Knöchel, Jane

“…Aims The aim of this study was to characterize the population pharmacokinetics of AZD8233, an antisense oligonucleotide (ASO) that targets the PCSK9 transcript…”
Get full text

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer by Quartino, Angelica L., Hillenbach, Carina, Li, Jing, Li, Hanbin, Wada, Russell D., Visich, Jennifer, Li, Chunze, Heinzmann, Dominik, Jin, Jin Y., Lum, Bert L.

“…Purpose To characterize the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast cancer (EBC), assess the…”
Get full text

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors by Quartino, Angelica L., Li, Hanbin, Kirschbrown, Whitney P., Mangat, Ranvir, Wada, D. Russell, Garg, Amit, Jin, Jin Y., Lum, Bert

“…Purpose The aim of the study was to characterize the population pharmacokinetics (PK) of the intravenous formulation of trastuzumab, assess the impact of…”
Get full text

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis by Kawakatsu, Sonoko, Zhu, Rui, Zhang, Wenhui, Tang, Meina T., Lu, Tong, Quartino, Angelica L., Kågedal, Matts

“…Clinical trials in patients with ulcerative colitis (UC) face the challenge of high and variable placebo response rates. The Mayo Clinical Score (MCS) is used…”
Get full text

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling by Netterberg, Ida, Karlsson, Mats O., Nielsen, Elisabet I., Quartino, Angelica L., Lindman, Henrik, Friberg, Lena E.

“…Aims Early identification of patients with febrile neutropenia (FN) is desirable for initiation of preventive treatment, such as with antibiotics. In this…”
Get full text

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

“…Purpose To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous…”
Get full text

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps by Zhu, Rui, Owen, Ryan, Wilkins, Justin, Schoemaker, Rik, Tian, Xianbin, Gautier, Aurelie, She, Gaohong, Vadhavkar, Shweta, Cheu, Melissa, Wong, Kit, Omachi, Theodore A., Putnam, Wendy S., Quartino, Angelica L.

“…The anti-immunoglobulin E (IgE) antibody, omalizumab (Xolair), is approved in the United States for the treatment of allergic asthma and chronic spontaneous…”
Get full text

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study by Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.

Get full text

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer by Quartino, Angelica L., Li, Hanbin, Jin, Jin Y., Wada, D. Russell, Benyunes, Mark C., McNally, Virginia, Viganò, Lucia, Nijem, Ihsan, Lum, Bert L., Garg, Amit

“…Purpose The NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the…”
Get full text

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839 by Sparve, Erik, Quartino, Angelica L, Lüttgen, Maria, Tunblad, Karin, Gårdlund, Anna Teiling, Fälting, Johanna, Alexander, Robert, Kågström, Jens, Sjödin, Linnea, Bulgak, Alexander, Al-Saffar, Ahmad, Bridgland-Taylor, Matthew, Pollard, Chris, Swedberg, Michael D B, Vik, Torbjörn, Paulsson, Björn

“…Corrected QT interval (QTc) prolongation in humans is usually predictable based on results from preclinical findings. This study confirms the signal from…”
Get more information

Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia by Bogason, Alex, Quartino, Angelica L., Lafolie, Pierre, Masquelier, Michèle, Karlsson, Mats O., Paul, Christer, Gruber, Astrid, Vitols, Sigurd

“…WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • In vitro studies show that daunorubicin (DNR) cytotoxicity decreases with increasing cell density because of a high…”
Get full text

Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloidleukaemia by Bogason, Alex, Quartino, Angelica L., Lafolie, Pierre, Masquelier, Michèle, Karlsson, Mats O., Paul, Christer, Gruber, Astrid, Vitols, Sigurd

“…center dot In vitro studies show that daunorubicin (DNR) cytotoxicity decreases with increasing cell density because of a high cellular uptake and depletion of…”
Get full text